HOME >> MEDICINE >> NEWS
Margin Width The Key To Control Of Ductal Carcinoma In Situ Of The Breast

USC New England Journal Of Medicine Study Urges Caution In Use Of Radiation Therapy

LOS ANGELES, May 5, 1999 - Patients with one of the most common and curable forms of breast cancer may be undergoing radiation therapy unnecessarily, according to a University of Southern California study to be published in the May 13 New England Journal of Medicine.

The study, headed by Melvin J. Silverstein, M.D., medical director of the Harold E. and Henrietta C. Lee Breast Center at the USC/Norris Comprehensive Cancer Center, examines ductal carcinoma in situ (DCIS), a noninvasive breast cancer that has been the subject of a recent heated debate over treatment. Until 1980, DCIS was a relatively uncommon disease, representing only about 1 percent of all newly diagnosed cases of breast cancer. During the past two decades - as mammography has become more widely used and technically better - the number of new cases has increased dramatically.

Today DCIS represents as much as 40 percent of new breast cancer cases diagnosed by mammography, and estimates suggest that approximately 40,000 new cases of DCIS will be diagnosed this year in the U.S. Seventy to 80 percent of these patients are eligible for breast preserving lumpectomy rather than mastectomy. But opinion is currently divided on whether radiation therapy is necessary for all DCIS patients who choose lumpectomy.

In the NEJM article, Silverstein, a surgical oncologist, and colleagues found that radiation therapy does not appear to benefit patients where the margin width - the distance between the boundary of the lesion and the edge of the excised specimen - is 10 millimeters or more.

"Wide margin width makes complete excision more likely," says Silverstein. "Since DCIS is a noninvasive cancer that does not spread (metastasize), complete excision should cure the patient. These findings will have important ramifications for thousands of women with the disease. These data suggest that radi
'"/>

Contact: Mary Ellen Stumpl or Brenda Maceo
maceo@hsc.usc.edu
323-442-2830
University of Southern California
13-May-1999


Page: 1 2 3 4

Related medicine news :

1. Hopkins Institute for Global Tobacco Control receives elite recognition from PAHO/WHO
2. Controlling hormones could reduce risk of strokes in younger people
3. Controlling pain with your brain
4. Five more African countries to benefit from Schistosomiasis Control Initiative
5. Controlled study after Dutch caf fire highlights teen mental-health problems after disasters
6. Control valve within heart cells could protect body during heart attacks
7. Grant of 20 million to establish the Schistosomiasis Control Initiative
8. Controlled crying reduces infant sleep problems
9. Controlling blood pressure early prevents heart disease in elderly
10. AAPS Workshop to Examine Chemistry and Manufacturing Controls Trials, Emerging Products
11. Revolutionary New Procedure That Creates Controlled Heart Attack Performed For First Time In Southern California At Cedars-Sinai Medical Center

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Margin Width The Key Control Ductal Carcinoma Situ The Breast

(Date:7/30/2014)... New York City, NY (PRWEB) July 30, 2014 ... Memorial & Museum at Ground Zero, the Ground Zero Museum ... confusion in recent tour bookings. Says the Museum Workshop's Carole ... tour and museum on all the major travel sites who ... Our description is now crystal clear as to what we ...
(Date:7/30/2014)... NY, July 30, 2014We have pills to ease pain, to ... conditions, and to enhance our sexual and athletic prowess. Why ... and could we benefit from taking fewer pills? This provocative ... The Role and Fantasy of Pills in Modern Medicine ," ... , a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... in Manchester have identified a protein that could help ... a treatment that makes radiotherapy more effective, according to ... Cancer (BJC). , The team from The University ... that patients whose bladder tumour had high levels of ... from having carbogen oxygen mixed with carbon dioxide ...
(Date:7/30/2014)... Up to 20 percent of Parkinson,s disease (PD) ... but largely unrecognized challenge: the occurrence of impulse ... behavior, eating, or spending. Yet the presence of ... complicate treatment options. A team of investigators from ... of Pennsylvania and the Parkinson,s Disease Research, Education ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: